- Home
- SRV vs INMB Comparison
SRV vs INMB Comparison
Compare SRV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 34.3M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRV | INMB |
|---|---|---|
| Price | $44.55 | $1.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.87 |
| AVG Volume (30 Days) | 63.2K | ★ 492.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,000.00 |
| Revenue This Year | N/A | $264.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.24 | $1.16 |
| 52 Week High | $46.43 | $11.64 |
Technical Indicators
Market Signals| Indicator | SRV | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 38.18 |
| Support Level | $42.39 | $1.19 |
| Resistance Level | $46.40 | $1.48 |
| Average True Range (ATR) | 0.93 | 0.11 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 48.05 | 17.74 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.